As of Aug 17
| -1.07 / -2.31%|
The 31 analysts offering 12-month price forecasts for Novo Nordisk have a median target of 45.77, with a high estimate of 55.24 and a low estimate of 31.73. The median estimate represents a +0.96% increase from the last price of 45.34.
The current consensus among 33 polled investment analysts is to Hold stock in Novo Nordisk. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.